Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00491634 | Treosulfan-based Conditioning for Transplantation in AML/MDS | completed | Phase 2 | 24 | Dr. Avichai Shimoni MDOTHER_GOV | 1 | Dec 2, 2015 | clinicaltrials |
| NCT01321346 | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT02034227 |
| Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia |
| terminated |
| Phase 1 / Phase 2 |
| 6 |
| SpirogenINDUSTRY |
| 1 |
| Nov 23, 2015 |
| clinicaltrials |
| NCT01277484 | Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AML(PODAC) | unknown | Phase 1 | 19 | Seoul St. Mary's HospitalOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01192945 | Non-interventional Study With Azacitidin (Vidaza®)(Piaza) | completed | — | 150 | iOMEDICO AGINDUSTRY | 1 | Nov 13, 2015 | clinicaltrials |
| NCT02189824 | Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation(SCRAMBLE) | unknown | Phase 1 | 12 | University of SydneyOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT02006004 | Epidemiologic Registry PETHEMA LMA 2013 | completed | — | 1,000 | PETHEMA FoundationOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01149408 | Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients | completed | Phase 1 | 3 | University of UtahOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)(BRIDGE) | completed | Phase 2 | 86 | Technische Universität DresdenOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT02188290 | Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation | completed | — | 178 | Kiadis PharmaINDUSTRY | 6 | Oct 6, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT02502968 | BL-8040 Addition to Consolidation Therapy in AML Patients(BLAST) | unknown | Phase 2 | 194 | Dr. Petra TschanterOTHER | 1 | Sep 21, 2015 | clinicaltrials |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01127009 | Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients | terminated | Phase 1 | 55 | AstraZenecaINDUSTRY | 2 | Aug 11, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00407966 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00533078 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies(LUNCH1) | completed | Phase 2 | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
| NCT02261779 | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible(TCP-AML) | unknown | Phase 1 / Phase 2 | 16 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Jul 7, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT01369368 | Treatment of Acute Leukemia Relapse After Allotransplantation | unknown | Phase 1 / Phase 2 | 20 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00957385 | Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients | completed | Phase 2 | 24 | University Health Network, TorontoOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01041443 | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT02461121 | HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | completed | Phase 3 | 156 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00678275 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | completed | Phase 3 | 161 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 6 | Mirati Therapeutics Inc.INDUSTRY | 3 | May 8, 2015 | clinicaltrials |
| NCT01146223 | Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia | completed | — | 10 | Children's Oncology GroupNETWORK | 1 | May 7, 2015 | clinicaltrials |
| NCT01149915 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | completed | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT02016833 | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | completed | — | 15 | PX BiosolutionsINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00885508 | A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q(GFM-Chimio-Rev) | unknown | Phase 2 | 85 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 24, 2015 | clinicaltrials |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | terminated | Phase 1 | 12 | New York Medical CollegeOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT01889407 | Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients | unknown | — | 94 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00383474 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01332786 | Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia | completed | Phase 1 | 27 | University Health Network, TorontoOTHER | 2 | Apr 15, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2015source: clinicaltrials